Vor Biopharma Inc (VOR) Stock Price, Quote & News

Company Profile

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 655 6580

Website: www.vorbio.com

Address:

100 Cambridgepark Drive, Suite 101, Cambridge, United States

hustleyank Feb. 23 at 4:24 PM

$VOR lol told yah

0 · Reply

_EmproX Feb. 23 at 3:47 PM

$SLND $SLS $VOR $KXIN <>

0 · Reply

Magic2001 Feb. 19 at 11:21 PM

$VOR Vor Biopharma (VOR) is at $13.310 (+0.83%) http://uk.investing.com/equities/vor-biopharma?utm_source=investing_app&utm_medium=share_link&utm_campaign=share_instrument

0 · Reply

__ChartMenace Feb. 19 at 5:43 PM

$BINI $VOR $BIAF $LONA ∆

1 · Reply

__ChartMenace Feb. 17 at 6:30 PM

$VOR $BIAF $LONA $ECDA e

0 · Reply

look2hook Feb. 17 at 2:39 PM

$VOR Push!

0 · Reply

look2hook Feb. 13 at 2:51 PM

$VOR I think we're gonna see a big bounce today. Inflation low and small caps should boost!

0 · Reply

ahab Feb. 11 at 9:19 PM

$VOR !2 /10/ 25 short, not so much for the $BBAI bear. Just random not cherry picked

0 · Reply

hustleyank Feb. 11 at 5:10 PM

$VOR buying area

0 · Reply

EdwardBrown839 Feb. 11 at 3:36 PM

$VOR Vor Biopharma; gene-edited cell therapies for AML; early-stage platform; high scientific and regulatory risk; partnership-dependent.

1 · Reply

Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference

Jan 6, 2026, 8:00 AM EST - 6 weeks ago

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 23, 2025, 4:01 PM EST - 2 months ago

Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

Dec 15, 2025, 8:00 AM EST - 2 months ago

Vor Bio Announces $150 Million Private Placement

Nov 13, 2025, 4:01 PM EST - 3 months ago

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 11, 2025, 9:43 AM EST - 3 months ago

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

Nov 10, 2025, 9:56 PM EST - 3 months ago

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Nov 10, 2025, 4:01 PM EST - 3 months ago

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

Nov 8, 2025, 11:45 AM EST - 3 months ago

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Nov 7, 2025, 8:00 AM EST - 3 months ago

Vor Bio to Participate in Upcoming Investor Conferences

Nov 3, 2025, 8:00 AM EST - 4 months ago

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Oct 31, 2025, 4:30 PM EDT - 4 months ago

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 29, 2025, 11:01 AM EDT - 4 months ago

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Oct 22, 2025, 4:30 PM EDT - 4 months ago

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease

Oct 17, 2025, 8:00 AM EDT - 4 months ago

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025

Oct 16, 2025, 8:00 AM EDT - 4 months ago

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025

Sep 29, 2025, 7:00 AM EDT - 5 months ago

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Sep 25, 2025, 11:48 AM EDT - 5 months ago

Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise

Sep 23, 2025, 8:00 AM EDT - 5 months ago

Vor Bio Appoints Navid Z. Khan, Ph.D.

Sep 17, 2025, 9:00 PM EDT - 5 months ago

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Sep 17, 2025, 4:15 PM EDT - 5 months ago

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Sep 12, 2025, 4:15 PM EDT - 5 months ago

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 2, 2025, 8:00 AM EDT - 6 months ago

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Aug 27, 2025, 8:00 AM EDT - 6 months ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Aug 13, 2025, 11:15 AM EDT - 6 months ago

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Aug 13, 2025, 8:30 AM EDT - 6 months ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Aug 4, 2025, 8:30 AM EDT - 7 months ago

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Jul 21, 2025, 8:30 AM EDT - 7 months ago

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Jul 18, 2025, 4:00 PM EDT - 7 months ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 17, 2025, 8:30 AM EDT - 7 months ago

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Jul 10, 2025, 4:00 PM EDT - 8 months ago

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Jul 1, 2025, 4:00 PM EDT - 8 months ago

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 2:31 PM EDT - 8 months ago

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Jun 25, 2025, 4:50 PM EDT - 8 months ago

Vor Bio Announces $175 Million Private Placement

Jun 25, 2025, 4:45 PM EDT - 8 months ago

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

May 8, 2025, 8:30 AM EDT - 10 months ago

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Feb 13, 2025, 8:00 AM EST - 1 year ago

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Feb 3, 2025, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 9:00 AM EST - 1 year ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Dec 27, 2024, 9:00 AM EST - 1 year ago

Vor Bio Announces $55.6 Million Private Placement

Dec 9, 2024, 7:30 AM EST - 1 year ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Sep 6, 2024, 9:35 AM EDT - 1 year ago

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Sep 5, 2024, 4:01 PM EDT - 1 year ago

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

May 9, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

May 2, 2024, 4:01 PM EDT - 1 year ago

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Mar 20, 2024, 4:05 PM EDT - 2 years ago

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

hustleyank Feb. 23 at 4:24 PM

$VOR lol told yah

0 · Reply

_EmproX Feb. 23 at 3:47 PM

$SLND $SLS $VOR $KXIN <>

0 · Reply

Magic2001 Feb. 19 at 11:21 PM

$VOR Vor Biopharma (VOR) is at $13.310 (+0.83%) http://uk.investing.com/equities/vor-biopharma?utm_source=investing_app&utm_medium=share_link&utm_campaign=share_instrument

0 · Reply

__ChartMenace Feb. 19 at 5:43 PM

$BINI $VOR $BIAF $LONA ∆

1 · Reply

__ChartMenace Feb. 17 at 6:30 PM

$VOR $BIAF $LONA $ECDA e

0 · Reply

look2hook Feb. 17 at 2:39 PM

$VOR Push!

0 · Reply

look2hook Feb. 13 at 2:51 PM

$VOR I think we're gonna see a big bounce today. Inflation low and small caps should boost!

0 · Reply

ahab Feb. 11 at 9:19 PM

$VOR !2 /10/ 25 short, not so much for the $BBAI bear. Just random not cherry picked

0 · Reply

hustleyank Feb. 11 at 5:10 PM

$VOR buying area

0 · Reply

EdwardBrown839 Feb. 11 at 3:36 PM

$VOR Vor Biopharma; gene-edited cell therapies for AML; early-stage platform; high scientific and regulatory risk; partnership-dependent.

1 · Reply

checkthef Feb. 11 at 2:29 PM

$VOR im in

0 · Reply

hustleyank Feb. 10 at 6:15 PM

$VOR you had your chance Going much higher

0 · Reply

hustleyank Feb. 9 at 2:50 PM

$VOR institutions adding I see

0 · Reply

YakoCapital Feb. 6 at 5:38 PM

$VOR Glad I grabbed some att $12

0 · Reply

Focalalria Feb. 5 at 8:59 PM

$VOR February 5, 2026 SCHEDULE 13G/A - Description SCHEDULE 13G/A. - In SEC Filings available on VOR website. What is it exactly?

1 · Reply

Stormfury66 Feb. 1 at 5:15 PM

$VOR Agree 100 % ADD or Buy at these levels loading zone

1 · Reply

Sharpwon Jan. 30 at 10:51 PM

$VOR what is this company and their pipeline worth? That’s the reason to invest here in my view. The swings of bios allow for patient buying zones on short and long term gains. Stick to your plan. Easy money in this sector at times but is very bumpy as well.

0 · Reply

Stormfury66 Jan. 30 at 3:38 PM

$VOR SUPPORT 13.49 .. added here waiting to see if support holds , bio is done across the board today so going to hold & or ADD no matter what this will spike if not today next week DONOT SELL AT THESE LEVELS GREAT ENTRY OR ADD

1 · Reply

Stormfury66 Jan. 30 at 3:34 PM

$VOR LOADING ZONE .. Buy & or ADD

0 · Reply

Stormfury66 Jan. 30 at 2:56 PM

$VOR Start loading , save some powder in case dips to 13.49 support level .. ADD HERE but save powder

0 · Reply

Stormfury66 Jan. 30 at 2:46 PM

$VOR 13.49 support , 15.10 resistance push through that on volume then significant gains spread the word jump in spike the volume for nice returns !

0 · Reply

Stormfury66 Jan. 30 at 2:43 PM

$VOR Needs to clear resistance of 15.10 to spike next leg to 16 This trades on volume extremely volatile don’t get spooked eventually chug to 18

0 · Reply

Market Cap	141.07M
Revenue (ttm)	0.00
Net Income (ttm)	-116.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	424,000
Avg Vol	2,035,028
Day's Range	N/A - N/A
Shares Out	10.41M
Stochastic %K	51%
Beta	2.02
Analysts	Strong Sell
Price Target	$38.67